Background: Genome Wide Association Studies (GWAS) have had limited success when applied to complex diseases. Analyzing SNPs individually requires several large studies to integrate the often divergent results. In the presence of epistasis, multivariate approaches based on the linear model (including stepwise logistic regression) often have low sensitivity and generate an abundance of artifacts.
Introduction
Almost a decade after the completion of the Human Genome Project [1] , the scientific and medical advances hoped for from genome-wide association studies (GWAS) have not yet been realized. After early successes with diseases where a single haplotype confers all or most risk [2] , the same statistical approaches have often produced ambiguous results when applied to complex diseases [3, 4] . Increasing the sample size (to tens of thousands of subjects as suggested [5] ) is impractical for rare disease forms, and also greatly increases the duration and cost of data collection. Improving accrual by broadening the inclusion criteria increases variance and thus requires yet larger samples; a vicious cycle. Moreover, increasing sample size in a nonrandomized study may, somewhat paradoxically, increase the risk of false positives [6, 7] .
Several mutations within a gene may contribute to the risk of common diseases and several SNPs may have become associated with the same mutation over time. One risk factor's contribution may depend on the presence of others and sets of mutations may confer more risk if they affect both chromosomes (compound heterozygosity). Hence, any statistical approach based on p-values derived one SNP at a time (ssGWAS) is ill-suited to identify the short-range epistasis involved [8] . (Following Fisher [9] , the term 'epistasis' will be used for any deviation from independence, be it between neighboring SNPs, intragenic regions or genes.) Analyzing diplotypes (sets of neighboring SNPs with unknown phase) comprehensively would be preferable [10] , yet traditional multivariate methods [11] including linear/logistic regression (lr) assume independence and additivity/multiplicativity of risk factors to yield computationally simple algorithms. Making unrealistic assumptions, such as linearity, may easily lead to meaningful non-linear relationships being overlooked (false negatives). More importantly, random errors, not subject to biological constraints, may occasionally fulfill these assumptions, so that the most 'significant' results are often false positives.
Association studies, in general, are exploratory 'selection procedures' [12] to generate, rather than confirm hypotheses. Even though the same algorithms are used as in confirmatory tests, 'p-values' merely serve to sort candidates, so that a sufficiently large selection of candidate genes will include the most interesting genes with high power. Even minor differences in the composition of the study population can result in different subsets of genes being selected [13] , and each could help with understanding a different aspect of the disease etiology when confirmed using mouse studies or clinical trials. Hence, the challenge in improving GWAS is to reduce artifacts caused by applying oversimplifying approaches to complex diseases (analyzing one SNP at a time, assuming independence and additivity of effects) while incorporating more knowledge to increase the sensitivity for detecting biologically relevant subsets of the genes involved.
With the advent of mainframe computers, more complex calculations (e.g., factor analysis) became feasible. More recently, personal computers triggered the development of resampling methods. Now we are, again, entering an era of advances in computational biostatistics, where massive-parallel computing has spurred the methodological advances making wide-locus GWAS based on a nonparametric approach (µGWAS, based on u-statistics for structured multivariate data) feasible [14] . Below, we introduce two novel concepts. First, several 'tag' sets of 'genetically indistinguishable' SNPs [15] are typically scattered across a linkage disequilibrium (LD) block, yet traditional methods cannot differentiate between 'permuted' diplotypes containing members of the same tag sets in different order. µGWAS draws on the spatial structure of SNPs within a diplotype and expected LD from HapMap [16] to improve the resolution of GWAS to intragenic regions. Second, we apply the concept of 'information content of multivariate data' (µIC) [14] at several stages of the analysis to guard against artifacts. With these methodological advances, disease-relevant genes and intragenic regions can now be suggested from a single study, often of only a few hundred narrowly defined cases, rather than from a variety of large studies, turning GWAS from a technique to identify isolated SNPs into a powerful tool to generate plausible and testable hypotheses about the etiology of complex diseases.
Methods

µ-scores for diplotypes
It is often reasonable to assume that risk conferred by a heterozygous SNP lies somewhere between baseline risk and a homozygous SNP (having two risk alleles) that is, between the risk of a recessive and a dominant allele, respectively. U-statistics (including the Wilcoxon/MannWhitney U test [17] ) treat SNPs as ordinal (wildtype = < < = XX xX xx homozygous), but do not require the degree of dominance to be known. Treating diplotypes as multivariate data then avoids the need for assumptions about independence and relative importance of the SNPs, yet the theory [18] was never broadly developed owing to prohibitively high computational demand [19] . With GWAS, for instance, the number of 'polarities' (combinations of −1 = bad / 0 = irrelevant / +1 = good) increases exponentially with diplotype length, yet with massively parallel computing we were now able to include diplotypes up to length six.
Traditionally, one would have more confidence in a 'significant' locus if neighboring loci also show association [20] and add recombination information to the data displayed. Here we integrate the concepts behind this intuitive visual inspection into the statistical approach itself. Recently, µ-scores (U-scores for multivariate data) have been extended to reflect structures among variables with applications including sports [21] , policy making [22] , and medicine [14] . The proposed GWAS-specific structure is based on the notion that neighboring disease loci may have similar effects and that a disease locus may be in LD with both adjacent SNPs unless the SNPs are separated by a recombination hotspot (boundary between LD blocks) ( Figure 1 ). µGWAS starts with computing matrices representing the partial order of each SNP, combining pairs of these matrices into matrices representing the intervals, and, finally, combining SNP and interval matrices into a diplotype matrix from which the µ-scores are computed [14, 22] . As diplotype profiles are built from intervals around and between neighboring SNPs, diplotypes where members i X , i Y , and i Z of the tag sets (X), (Y), and (Z) appear in different order (permuted diplotypes), such as (X 1 , Y 1 , Z 1 ) versus (Y 1 , X 1 , Z 1 ) can be distinguished. This novel approach to incorporate knowledge of neighborhood relationships between SNPs increases power over merely combining all SNPs within a diplotype in a single step [14] , yet avoids the need for assumptions about dependencies and relative importance required when using linear combinations (weighted sums) of univariate scores. With GWAS based on lr (lrGWAS), one could work towards a similar goal by adding sequential interaction terms. Hence, we will compare µGWAS not only with ssGWAS for dominant, linear trend [23] , and recessive effects, but also with stepwise logistic regression with and without sequential interaction terms. Conceptual structure of chromosomal SNP-related intervals for disease loci in LD with three consecutive SNPs (X, Y, and Z), but not with a more distant SNP (A). SNPs X and Y are part of different LD-blocks, separated by a recombination hotspot. Hence, the interval between these two SNPs is excluded. The location indicating LD between SNPs A and X is highlighted. The inter-regional boundaries need not be known. LD: Linkage disequilibrium
Subjects
Childhood Absence Epilepsy (CAE) [24] , formerly known as 'petit mal', is characterized by frequent, short episodes of 'day dreaming'. Through trial and error of different combinations of valproic acid and various ion channel blockers, these absences can be controlled in approximately 75% of affected children [25] . For adult patients, etiracetam, an IL-1β inhibitor [26] was approved in November 1999, and a Caspase 1 inhibitor (VRT-765) is undergoing a controlled Phase IIb study [101] . CAE does not follow a simple Mendelian pattern of inheritance, although recurrence of epilepsy in families is high. A high concurrence in monozygotic twins and the absence of known exogenic factors make CAE an ideal model for studying the genetics of complex diseases and approaches to unravel their genetic risk factors to better match patients to existing drugs and identify new drug targets for patients who do not respond to existing drugs. The 185 CAE patients in this study were predominantly Caucasian (83%) and white Hispanic (10%) with the well-known female preponderance (115 female vs. 70 male patients). Average age of onset for absence seizures was 5.7 years. Patients were required to be seizure free on antiepileptic medication. Controls were selected from a publicly available database [103] . See Supplemental Material at www.futuremedicine.com/doi/duppl/10.2217/pgs.13.28 for details.
Results
Identifying Genes
As is typical for ssGWAS, especially with small samples, only two SNPs reached the customary s = −log 10 (p) > 7.5 level of significance with univariate tests (Figure 2 , black foreground), one in a non-coding region (chromosome 1, lr only), the other in the pseudogene EE1A1P12 (chromosome 2). Since ssGWAS was inconclusive and sequential interaction terms created an abundance of likely false positives with lrGWAS (see Supplementary Figure 2 ), even with regularization (AIC [27] ), the following discussion focuses on µGWAS vs. traditional lrGWAS. In the spirit of conducting a selection procedure [12, 28] , rather than confirmatory tests, p-values were used solely for the purpose of ranking the loci and. At any given level, lrGWAS had more 'significant' results, in general, including many likely false positives. Hence, methods were compared using similar arbitrary numbers of top regions (first comparison used only the top 6, second comparison used ≈20, third comparison used≈40; see Supplementary Table 1) , the latter cut-offs adjusted for display purposes ( Figure 2 ) to match commonly used s-values (µ: 7.5/7.0, lr: 8.0/7.5) Only one of the top six genes in lrGWAS (RBFOX1) ranks higher than r µ = 73 rd in µGWAS (5 th ), while the other four among the top six regions in µGWAS are also among the top 22 in lrGWAS (the above elongtion factor pseudogene EEF1A1P12; SYN3, synapsin III; FAT4; CREB5, Supplementary Table 1) . Of the top 17 µGWAS regions ( 7.5 s > ), 14 (82%) are known to be in genes directly related to the NOD/axonal guidance signaling/ataxin pathway (Figure 3) (16 th ). Hence, VRT-765 might be particularly effective for patients with a 'gain-of-function' mutation in NLRP3. Cytoskeleton dynamics: RHOA was upregulated in patients with intractable epilepsy [33] , yet the mechanism involved is unknown. Two genes known to regulate RHOA, OPHN1 (also known as ARHGAP41) and ARHGAP32 are among the top 10 genes with µGWAS, but rank only 99 th and 58 th, , respectively, in lrGWAS. The risk of epilepsy is increased in children with intellectual disabilities (ID), where ARHGAP32 has been implicated. Binding between ARHGAP32 and ATXN1 has been implicated in inherited ataxias [34] . OPHN1 is known to affect X-linked ID [35] and, thus, might explain the preponderance of CAE among girls. µGWAS adds a pair of binding partners downstream of RAC1 to the picture, RASSF8 (17 th ) and PARD3 (26 th ). Finally, the 'pseudogene' EEF1A1P12, being among the top 10 regions in both approaches, hints at an involvement of EEF1A1, which regulates CDC42. Hence, µGWAS uniquely provides a testable hypothesis about the mechanism by which RHOA is upregulated in some forms of epilepsy. Ataxin: Ataxias and epilepsy share genetic risk factors [36, 37] , including OPHN1 [38, 39] 
Detecting Epistasis and Selection
Among the genes involved in cytoskeleton dynamics, ARHGAP32, with known direct interactions with many of the key players, ranked 11 th in µGWAS, but only 58 th in lrGWAS. Moreover, it had two separate 'peaks' in µGWAS, one in the promoter region.
Epistasis between neighboring SNPs:
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LR Scores
Validation
In this analysis, we have reduced the potential for false positive results by taking advantage of the novel internal validation features made possible with µGWAS. During data preparation, we used a data quality µ-score based on a comprehensive assessment of missing data, HardyWeinberg equilibrium, short-range LD, and expected LD from HapMap information. During analysis, we have drawn on polarity conflict and lower than expected µIC ( Supplementary Figure 1) . Finally, we utilized µIC to indicate highly significant results with low µIC. Notably, none of the pathway related genes flagged as potentially unreliable are related to the genes downstream of RAC1 (Figure 2 ). Larger genes are both more likely to carry mutations and to have false positives. Still, although several of the genes identified are among the largest 5% (>200 kB) in the human genome, only 2 of the top 11 unique genes in µGWAS (CREB5 and BRE) and 3 of the top 13 unique genes in lrGWAS (DYSF, DOK6 and TMCO7) are 'direct hits' within the coding region (Supplementary Table 1 ). ARHGAP32 and OPHN1 were implicated by 'hits' in the stop or promoter regions, respectively, and thus, are not at an increased risk for being false positives due to their size.
The results on ARHGAP32 (Figure 4 ) are supported by further evidence. First, each of the six SNPs included in the two diplotypes is in high LD with several other SNPs ( Figure 4E ), for which the probe sequences differ and, thus, are not subject to the same calling errors. Second, only the two pairs of diplotypes having the highest association with disease risk by µ-scores were in high LD between the intragenic regions ( Figure 4C , horizontal dashed arrows), while lower risk diplotypes were unrelated. Not only is it highly unlikely for each of these results to occur by chance alone, it is virtually impossible that they could occur together, and in both independent populations. While this cannot rule out a false positive result due to association with factors beyond the etiology of epilepsy, these findings validate the ability of µGWAS to detect intragenic regions of biologically relevant epistatic patterns. Finally, the diplotype with the highest overall (exon 10 and promoter region) score µ (E,P) is clearly overrepresented among cases, with a prevalence of 14.1% (26 out of 185) and 6.5% (23 out of 354) in cases and controls, respectively, compared with 3.8% (7 out of 185) and 6.2% (22 out of 354) for the diplotypes with the lowest µ-scores, confirming that µ-scores are, in fact, reflecting disease risk.
As one would expect, µ and lr scores ( Figure 4 , right border) are correlated. The subjects with the pair of diplotypes having the highest µ (E,P) -scores ( Figure 4D ) also share a diplotype with a high lr-score, but the subjects scoring even higher in lr-scores ( Figure 4E ) comprise four different diplotypes. Interestingly, the largest of these groups differs only in the first SNP from a diplotype with low lr-and µ-scores (vertical arrows in Figure 4 D), consistent with the sensitivity of linear model results to outliers. As the partial ordering underlying µ-scores, which directly reflects an underlying functional model, results in more genetic uniformity among subjects with extreme scores, these more homogeneous sub-populations could then be selected for identification of functional variations through sequencing.
Conclusion
With GWAS of complex diseases, only a few solitary SNPs typically stand out from the noise, especially in small studies, and this study is no exception. Different compositions of rare disease variants across studies almost inevitably result in different SNPs being 'significant', so that validation in independent ssGWAS requires many large studies until a testable hypothesis emerges. µGWAS, in contrast, related approved and experimental drugs to functional clusters of genes along a known pathway in a study of 185 well characterized cases only. ssGWAS can efficiently screen for loci, where a single haplotype confers all or most of the risk (EEF1A1P12). lrGWAS has advantages when the effects of SNPs are at least approximately independent and additive (as they might be in some transporters and ion channels). With more complex processes, however, like the interactions of ARHGAP32 with its various binding and activation partners, not constraining results by making overly simplistic assumptions leads to biologically relevant hypotheses about functionally related genes clustered around biologically relevant pathways. Pathway-based approaches [42] and Gene Set Enrichment Analysis [43] , combine results of univariate statistics using assumptions regarding the relative importance of genes and prior declarations of relatedness among genes instead of observed interactions. However, this analysis suggests that few, if any, pathway genes themselves may carry mutations in common diseases, unless they are members of redundant complexes (NLRP3, SYN3, and PARD3, Figure 3 ), in which case multiple genes may need to be knocked out to produce a phenotype [44] .
Wide-locus GWAS aims at accounting for compound heterozygosity, different haplotypes carrying the same mutation, and epistasis between nearby disease loci. Hence, functional regions can be identified more easily, even when the contribution of individual SNPs would be difficultif not impossible -to detect. Many traditional statistical methods, however, have deficiencies for relevant types of epistasis. ARHGAP32, which ranked 10 th among µGWAS genes and was validated through the distinct epistatic pattern among the highest-risk allelotypes confirmed in sequencing (Figure 4) , did not even appear among the top 50 lrGWAS regions.
µGWAS requires neither Hardy-Weinberg equilibrium nor independence or additivity/ multiplicativity of genetic effects, thereby improving sensitivity for non-linear effects (including evolutionary selection, Figure 4 , horizontal dashed arrows, and Supplementary Table 1 ). Adding sequential interactions and recombination hotspots improves resolution, rather than creating artifacts. Together with OPHN1 (also unique to µGWAS at rank 8), this study provides a plausible hypothesis why expression of RHOA is upregulated in some forms of epilepsy [33] .
Increased expression of RHOA was recently associated with some epilepsies [33] . Both OPHN1 and ARHGAP32 interact with both RHOA and PI3K (Figure 3 ), a drug target currently investigated in cancer [45] and inflammatory diseases [46] . Wortmannin, an inhibitor of PI3K, attenuates effects of seizures in rats [47] and PX-866 (a oral drug derivative of Wortmannin, in a phase II prostate cancer trial 102), targets PI3K. If our results are confirmed and hold for patients with other epilepsies as well, this might lead to novel therapeutic approaches to treat patients whose seizures do not respond to drugs targeting ion channels, the inflammasome, or the nucleosome. As this study included only patients whose seizures were controlled by valproic acid and/or ion channel blockers, these genes may play an even larger role in other populations.
A particular advantage of µGWAS is the ability to guide the interpretation of data patterns in terms of biological function. Sorting diplotypes by the overall risk they confer ( Figure 4C ), rather than by linear weight scores lacking direct biological interpretation ( Figure 4D ) provided compelling evidence for intragenic epistasis ( Figure 4C ), facilitated validation ( Figure 4F ), and generated testable hypotheses regarding the function of underlying mutations. By utilizing the order of neighboring SNPs and HapMap information about their expected LD, µGWAS can often identify functional intra-genetic regions, whereas the resolution of lrGWAS, irrespective of sample size, is typically limited to an LD block as a whole. For instance, this analysis suggests that the combinations of diplotypes with the highest µ-score in either of the ARHGAP32 regions have been selected for because they partially compensate for each other. Epistasis might also explain why knocking out the entire ARHGAP32 gene produced no obvious phenotype in mice [48] .
In summary, our results show that genetic risk factors for complex diseases cannot be adequately addressed with ssGWAS alone and that the computationally simple lrGWAS approach may be insensitive to complex forms of epistasis. Reducing artifacts by avoiding models motivated by computational convenience, rather than biological plausibility reduces the need for independent studies to guard against false positive results from model misspecifications. For comparative effectiveness research and personalized diagnostics to live up to their expectations, cases and controls need to be closely matched to the population or patient involved. Adequately controlling for genetic and environmental confounders when selecting appropriate cases and controls is essential to tease out predictive factors. This goal is much easier to achieve with only a few hundred subjects, rather than several thousands to be matched. Finally, subset analyses of phase-III trials and published epidemiological studies could rapidly reveal novel insights for drug development.
Future perspective
The Ras pathway is known to be involved in both cancers and many developmental disorders [49] , so the findings here suggest that identifying genetic risk factors modulating this pathway may help in better using information from sequencing patients when targeting pharmacological interventions not only in cancers, but also in other neurodevelopmental diseases other than CAE, including ID and autism spectrum disorders [31] . With more appropriate statistical methods and more powerful computational tools becoming available, the focus in screening for genetic risk factors of complex diseases can now shift from individual SNPs scattered across the genome to clusters of genes around biologically meaningful pathways. With further advances in computational resources, µGWAS can be extended from epistasis across recombination hotspots (Figure 1 ) to epistasis between intragenic regions (such as those seen in Figure 4) , and between genes ( Figure 3) . As µGWAS can provide therapeutically relevant information from substantially smaller sample sizes, decisions in personalized medicine and comparative effectiveness research can be based on samples fine-tuned to the particular patient or population, respectively. As a few hundred subjects experiencing adverse events or lack of a treatment effect and matched controls from the same population suffice to determine genetic risk factors, data from previous or upcoming Phase III trials can now be effectively mined to determine subpopulations at risk of adverse events and identify directions for development of drugs with a broader target population. 
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Executive Summary
Introduction
• The requirement for (tens of) thousands of subjects with univariate statistical approaches limits the usefulness of genome-wide association studies (GWAS) for comparative effectiveness research, personalized diagnostics / treatment, and subgroup analyses of phase III trials • Several mutations within an intragenic or promoter region may contribute to the risk of common diseases.
• GWAS using multivariate statistical approaches based on unrealistic assumptions (e.g., independence and additivity) implicit to linear/logistic regression (lrGWAS) has low power to detect meaningful relationships and carries a high risk of false positives.
• The advent of massively parallel computing has spurred the development of statistical methods that requiring fewer unrealistic assumptions, including GWAS based on U-statistics for structured multivariate data (µGWAS).
Methods
• Extending µ-statistics to reflect linkage-disequilibrium (LD) structures in the data increases the power and avoids artifacts.
• A well-characterized sample of 185 children with childhood absence epilepsy was analyzed as an example.
Results
• With single-SNP GWAS, only two SNPs reached the customary level of significance.
• Of the top 17 regions in µGWAS, 14 (82%) were in genes related to a known disease-related signaling pathway, compared to only 8 (36%) of the top 22 regions in lrGWAS.
• µGWAS was able to detect intragenic regions (i.e., exon, promoter) and LD structures, suggesting evolutionary selection.
Conclusion
• Avoiding overly simplistic assumptions leads to biologically relevant hypotheses about functionally related genes clustered around biologically relevant pathways.
• The pathway identified by µGWAS contains targets of approved anti-epileptic drugs and a gene being investigated as a cancer drug target.
• Reducing artifacts by avoiding biologically implausible assumptions guards against false positive results from model misspecifications.
• By reducing the GWAS sample sizes to a few hundred subjects only, µGWAS enables personalized medicine, comparative effectiveness research, and subset analyses of epidemiological studies / phase III trials.
• Introduces the concept of selection-procedures as opposed to confirmatory tests. • Derives the asymptotic distribution of linear rank tests based on u-scores. 19. Li H: U-statistics in genetic association studies.
Hum Genet 131 (9), 1395-1401 (2012).
• Exclusion of data based on low data quality µ-scores, including low ratio of observed vs. expected LD from HapMap is a unique feature of µGWAS. HapMap information can also be used to determine whether to consider recombination hotspots in the diplotype structure. (C) µStat discrimination utilizes the same information about the diplotype structure as logistic regression with sequential interaction terms. Excluding a polarity in µGWAS based on polarity conflict or low µIC compared to µIC among its supersets serves a similar purpose as excluding SNPs in logisktic regression based on the AIC. (D) Identification of significant results with low reliability is a unique feature of µGWAS. Figure 2 legend for details; bottom: lrGWAS with sequential interaction. Genes implicated by only one of the methods are shown with that method against the dark background of univariate results.
Supplementary
Cases
The study was approved by the IRBs of both the Mount Sinai School of Medicine and The Rockefeller University. Our cases included 185 patients with CAE according to the criteria devised by the International League against Epilepsy [50] . To reduce genetic heterogeneity, we required that patients did not have seizures other than febrile seizures prior to the onset of absence seizures, that they had at least one EEG with a 3 Hz spike-wave pattern, and that all patients were be seizure free on antiepileptic medication. Only 21 patients developed generalized tonic clonic seizures after the onset of absence seizures, and only one patient had myoclonic jerks.
Controls
Only the 8,231 controls that were typed for the Illumina HumanHapmap 300 array or higher were considered. To reduce confounding due to population stratification and the risk of spurious results, we genotypically matched three sets of controls to the cases by ancestry information markers [51] using distinct criteria, and we then performed a stratified analysis [52] adjusted for overlaps of subjects between strata. We randomly split the top 96 ancestry informative markers (AIMS) [51] into two sets to create distinct control groups matched for different variables. Matching was performed in two different ways: 1) matching the frequency distribution at those AIMS on a population level and 2) matching cases individually to controls for as many genotypes as possible at either of the AIMS subsets, giving preference to controls matching by several sets of criteria. To check the quality of our matching algorithms, we calculated lambda (the inflation factor of the chi square distribution [53] ) from all genotyped loci in the respective case/control samples. Lambda with all three control groups was 1.00-1.01, consistent with absence of population stratification. The availability of three different control groups is helpful to reduce the risk of false positives due to random variation in the control genotype frequencies.
Genotyping
To match the controls, we restricted the analysis to those markers included in the Illumina HumanHapmap300 SNPs. Genotyping was performed at the Illumina preferred vendor laboratory of the DNA Sequencing and Genotyping facility at Cincinnati Children's Hospital (CCHMC). We performed extensive data checking for quality assurance. First, the reported sex was validated using X-linked SNPs. Although µGWAS does not require SNPs to be in Hardy-Weinberg Equilibrium (HWE), we then inspected all SNPs that deviated from HWE (p < 0.001, 3589 SNPs) and visually inspected all loci with >10% missing calls. After the first 140 subjects, we switched from the Illumina HumanCNV370_Duo to the HumanCNV370_Quad chip, which, in general, provides higher quality calls. After the GeneTrain2 algorithm became available, we manually rescored all loci with >1% of missing calls and visually inspected all SNPs where the new algorithm did not substantially reduce or even inflated the number of missing calls. We also inspected all SNPs where a χ 2 test rejected the homogeneity between duo and quad chip case distributions (p<0.0001). After visual inspection, we removed all SNPs where 20% of calls were missing. If either >98% were AA or >98% were BB across cases and controls, the SNP was excluded as noninformative (minor allele frequency, MAF). Similarly, if two neighboring SNPs had >98% "identical" contingency tables, the SNP was also excluded as non-informative (LD). Missing data were recoded as interval censored, based on the sign of 'theta' (A−B)/(A+B). SNPs missing by design in the duo chip were excluded from the comparison. To guard against differences between chips, we included the χ 2 test for homogeneity across case distributions across chips when computing the data quality µ-scores.
Statistics
U-statistics for multivariate data have been recently extended to allow variables to be hierarchically structured [14] . Since then, details of the method have been repeatedly published (see [54] for an overview) with applications ranging from sports [21] and policy making [22] to medicine [14] .
As each of six neighboring SNPs could be either 'good', 'bad', or 'irrelevant', a comprehensive analysis requires 3 6 = 729 'polarities' (combinations of −1/0/+1) to be considered, and each of these multivariate analyses is substantially more complex than a univariate analysis. For each polarity, the allele profiles form a partial order (PO), where allele profile A confers more risk than profile B if it has the same risk alleles as profile B plus some additional risk alleles. Denoting risk alleles with capital letters, (Xx, YY, zz), for example, confers a greater risk than (Xx, Yy, zz), but the pairwise ordering of either profile with (xx, Yy, Zz) is ambiguous, because the contribution of Z to the overall risk vs. that of X and Y is unknown. The profile µ-score (u-scores for multivariate data) is the number of profiles with an unambiguously lower risk minus the number of profiles with an unambiguously higher risk. Treating loci with one unknown allele as 'interval-censored', i.e., as not-xx (xX or XX) or not-XX (xx or xX), respectively, further decreases ambiguities. One then compares disease categories by a linear rank test [55] applied to the µ-scores [18] . As the direction of each SNP's effect is unknown, many polarities need to be considered when screening for the one that best discriminates between disease categories.
Here, we first scored the subjects within each stratum, and then computed hierarchically structured µ-scores [14] , using a special case of such a hierarchical structure. At the first level of the hierarchy one computes the matrices of pairwise comparisons representing the order (partial order in case of censored calls) of the SNPs, e.g. in the context of Figure 1 , X, Y, and Z. At the second level of the hierarchy, the matrices of two adjacent SNPs are combined into a matrix for interval between these SNPs, e.g., (Y,Z), unless the two SNPs are separated by a recombination hotspot, where the matrix is filled with zeroes (X,Y)=0. Then, at the third level, the n single SNP and n−1 interval matrices are combined to obtain the diplotype matrix, from which the µ-scores were computed.
At each locus, we performed tests for diplotypes of length 1-6 centered at or above the locus. We allowed <50% of SNPs to be excluded from a diplotype, but not the first and the last, and considered all combinations of polarities (−1, 0, +1) among the SNPs included, except that the first and the last SNP as well as at least 50% of the SNPs included needed to be non-null. I.e., for a diplotype of length 5, the polarities (±1, ±1, ±1, ±1, ±1), (±1, 0, ±1, ±1, ±1), (±1, ±1, 0, ±1, ±1), (±1, ±1, ±1, 0, ±1), (±1, 0, 0, ±1, ±1), (±1, 0, ±1, 0, ±1), and (±1, ±1, 0, 0, ±1).
The effect and variance estimates of each block were then incorporated into a stratified Wilcoxon/Mann-Whitney type test statistic [52] . To adjust for the overlap between strata, the average across the three strata was weighted with an empirically confirmed √3, rather than 3.
By construction, tests based on µ-scores are sensitive to all monotonous (including dominant, trend, and recessive) alternatives.
As no particular hypotheses regarding specific loci were to be confirmed and most adjustments do not change the order of the results, no adjustment for multiple confirmative testing is warranted.
